loading
Dianthus Therapeutics Inc stock is traded at $17.53, with a volume of 269.99K. It is up +0.81% in the last 24 hours and down -19.22% over the past month. Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.
See More
Previous Close:
$17.39
Open:
$17.54
24h Volume:
269.99K
Relative Volume:
0.80
Market Cap:
$563.76M
Revenue:
$4.12M
Net Income/Loss:
$-56.68M
P/E Ratio:
-3.1626
EPS:
-5.5429
Net Cash Flow:
$-51.44M
1W Performance:
-4.86%
1M Performance:
-19.22%
6M Performance:
-31.79%
1Y Performance:
-18.88%
1-Day Range:
Value
$17.10
$18.01
1-Week Range:
Value
$16.91
$19.00
52-Week Range:
Value
$13.37
$32.27

Dianthus Therapeutics Inc Stock (DNTH) Company Profile

Name
Name
Dianthus Therapeutics Inc
Name
Phone
929-999-4055
Name
Address
7 TIMES SQUARE, NEW YORK
Name
Employee
78
Name
Twitter
Name
Next Earnings Date
2024-11-07
Name
Latest SEC Filings
Name
DNTH's Discussions on Twitter

Compare DNTH with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
DNTH
Dianthus Therapeutics Inc
17.53 576.63M 4.12M -56.68M -51.44M -5.5429
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.93 25.76B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
445.43 114.53B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.415 40.54M 0 0 0 0.00
Biotechnology icon
VRNA
Verona Pharma Plc Adr
84.10 6.44B 0 -153.72M -103.81M -2.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
490.81 65.13B 14.09B 4.50B 2.96B 39.28

Dianthus Therapeutics Inc Stock (DNTH) Upgrades & Downgrades

Date Action Analyst Rating Change
Dec-20-24 Initiated TD Cowen Buy
Oct-03-24 Initiated Oppenheimer Outperform
Jul-26-24 Initiated Robert W. Baird Outperform
Jun-27-24 Initiated Cantor Fitzgerald Overweight
May-16-24 Initiated H.C. Wainwright Buy
Feb-15-24 Initiated Stifel Buy
Dec-26-23 Initiated Jefferies Buy
Nov-22-23 Initiated Wedbush Outperform
Oct-30-23 Initiated Guggenheim Buy
Sep-28-23 Initiated Raymond James Outperform
Aug-25-22 Downgrade Goldman Buy → Neutral
Jan-06-22 Upgrade Goldman Neutral → Buy
Aug-20-21 Resumed Goldman Neutral
Aug-03-21 Downgrade JP Morgan Overweight → Neutral
Jul-22-21 Reiterated B. Riley Securities Buy
Jun-29-21 Initiated Cantor Fitzgerald Overweight
Jun-15-21 Initiated BTIG Research Buy
May-18-21 Initiated B. Riley Securities Buy
Jan-07-21 Initiated Mizuho Buy
Jun-08-20 Upgrade Goldman Neutral → Buy
Mar-25-19 Downgrade Goldman Buy → Neutral
Mar-15-19 Initiated Raymond James Outperform
View All

Dianthus Therapeutics Inc Stock (DNTH) Latest News

pulisher
04:08 AM

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Shares Acquired by Millennium Management LLC - Defense World

04:08 AM
pulisher
03:28 AM

BNP Paribas Financial Markets Makes New Investment in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - Defense World

03:28 AM
pulisher
Jun 01, 2025

Dianthus Therapeutics (NASDAQ:DNTH) Shares Down 5.2%Time to Sell? - MarketBeat

Jun 01, 2025
pulisher
May 31, 2025

Analysts Set Dianthus Therapeutics, Inc. (NASDAQ:DNTH) PT at $53.00 - MarketBeat

May 31, 2025
pulisher
May 30, 2025

Deutsche Bank AG Increases Holdings in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - Defense World

May 30, 2025
pulisher
May 29, 2025

Dianthus Therapeutics to Webcast Presentation at the Jefferies Global Healthcare Conference - The Manila Times

May 29, 2025
pulisher
May 29, 2025

Autoimmune Disease Biotech Dianthus Therapeutics CEO Takes Stage at Major Jefferies Conference - Stock Titan

May 29, 2025
pulisher
May 26, 2025

Northern Trust Corp Acquires 42,923 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - MarketBeat

May 26, 2025
pulisher
May 26, 2025

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Shares Purchased by Woodline Partners LP - MarketBeat

May 26, 2025
pulisher
May 26, 2025

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives Average Recommendation of “Buy” from Brokerages - Defense World

May 26, 2025
pulisher
May 25, 2025

Point72 Asset Management L.P. Reduces Stock Holdings in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - MarketBeat

May 25, 2025
pulisher
May 24, 2025

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Shares Acquired by Vestal Point Capital LP - MarketBeat

May 24, 2025
pulisher
May 23, 2025

Dianthus Therapeutics Appoints Simon Read, Ph.D., to Board of Directors - citybiz

May 23, 2025
pulisher
May 22, 2025

Dianthus Therapeutics appoints new board member - Investing.com Australia

May 22, 2025
pulisher
May 22, 2025

Dianthus Therapeutics Announces Board Changes and Elections - TipRanks

May 22, 2025
pulisher
May 22, 2025

Dianthus Therapeutics appoints new board member By Investing.com - Investing.com UK

May 22, 2025
pulisher
May 22, 2025

Former Novartis-Acquired CEO Joins Dianthus Board Ahead of Critical Phase 2 Data - Stock Titan

May 22, 2025
pulisher
May 21, 2025

Janus Henderson Group PLC Buys 136,314 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - MarketBeat

May 21, 2025
pulisher
May 20, 2025

Buy Rating Affirmed for Dianthus Therapeutics: Promising Clinical Potential of DNTH103 in CIDP Treatment - TipRanks

May 20, 2025
pulisher
May 19, 2025

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Position Raised by Octagon Capital Advisors LP - MarketBeat

May 19, 2025
pulisher
May 18, 2025

Robert W. Baird Has Lowered Expectations for Dianthus Therapeutics (NASDAQ:DNTH) Stock Price - MarketBeat

May 18, 2025
pulisher
May 18, 2025

FY2025 EPS Estimates for DNTH Lowered by Cantor Fitzgerald - Defense World

May 18, 2025
pulisher
May 18, 2025

Dianthus Therapeutics (NASDAQ:DNTH) Earns "Buy" Rating from HC Wainwright - MarketBeat

May 18, 2025
pulisher
May 17, 2025

Dianthus Therapeutics (NASDAQ:DNTH) Announces Quarterly Earnings Results, Beats Estimates By $0.04 EPS - MarketBeat

May 17, 2025
pulisher
May 17, 2025

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Shares Bought by Price T Rowe Associates Inc. MD - Defense World

May 17, 2025
pulisher
May 16, 2025

Wedbush Research Analysts Raise Earnings Estimates for DNTH - Defense World

May 16, 2025
pulisher
May 16, 2025

HC Wainwright Issues Positive Forecast for DNTH Earnings - Defense World

May 16, 2025
pulisher
May 16, 2025

Tower Research Capital LLC TRC Sells 944 Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - Defense World

May 16, 2025
pulisher
May 15, 2025

Robert W. Baird Issues Pessimistic Forecast for Dianthus Therapeutics (NASDAQ:DNTH) Stock Price - Defense World

May 15, 2025
pulisher
May 15, 2025

HC Wainwright Reaffirms Buy Rating for Dianthus Therapeutics (NASDAQ:DNTH) - Defense World

May 15, 2025
pulisher
May 14, 2025

Dianthus Therapeutics (NASDAQ:DNTH) Trading Down 6.1% Following Analyst Downgrade - Defense World

May 14, 2025
pulisher
May 13, 2025

DNTH: HC Wainwright & Co. Reiterates Buy Rating with $40 Target - GuruFocus

May 13, 2025
pulisher
May 13, 2025

DNTH Stock Target Price Lowered by Analyst Baird | DNTH Stock Ne - GuruFocus

May 13, 2025
pulisher
May 13, 2025

Breaking Down Dianthus Therapeutics: 5 Analysts Share Their Views - Benzinga

May 13, 2025
pulisher
May 13, 2025

Wedbush Adjusts Price Target on Dianthus Therapeutics to $34 From $36, Maintains Outperform Rating - marketscreener.com

May 13, 2025
pulisher
May 13, 2025

Dianthus (DNTH) Target Price Adjusted Amid Q1 Pipeline Update | - GuruFocus

May 13, 2025
pulisher
May 13, 2025

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial Results - The Manila Times

May 13, 2025
pulisher
May 13, 2025

Dianthus Therapeutics Reports Increased R&D Expenses - TipRanks

May 13, 2025
pulisher
May 12, 2025

Dianthus Therapeutics, Inc. (DNTH) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance

May 12, 2025
pulisher
May 11, 2025

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Position Lifted by Braidwell LP - MarketBeat

May 11, 2025
pulisher
May 10, 2025

Avidity Partners Management LP Lowers Holdings in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) - MarketBeat

May 10, 2025
pulisher
May 08, 2025

Dianthus Therapeutics, Inc. (DNTH) Reports Q4 Loss, Misses Revenue Estimates - MSN

May 08, 2025

Dianthus Therapeutics Inc Stock (DNTH) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$1.15
price up icon 6.48%
$31.19
price up icon 3.48%
$584.61
price up icon 1.98%
$306.09
price up icon 0.50%
$4.5994
price up icon 2.21%
$490.81
price up icon 0.11%
Cap:     |  Volume (24h):